



iNTeg-Risk: Early Recognition, Monitoring and Integrated Management of Emerging, New Technology Related Risks

iNTeg-Risk Meeting, Event, etc.

Brussels, December 2nd 2008

**Marc O. Schurr, Fabian Rieber
novineon Healthcare Technology Partners GmbH, Tuebingen, Germany**



novineon - introduction

Lead generation:

Research on technology leads for future medical products.

Concept development and prototyping:

Development of fundamental solutions for the product and manufacture of prototype.

Preclinical studies:

Continuing medical testing in parallel to technical development of prototypes. Standardized experimental validation of the new product.

Regulatory environment:

Establishment of data and documentation for regulatory filing. Clinical evaluation according to MDD.

Clinical studies:

Preparation and management of opinion-leader focussed clinical studies.

Assess public health and medical issues related to monitoring of emerging risks due to Nano-materials

T1.3.1. Public health and medical issues related to monitoring of emerging risks in production, storage and transport of nano-materials on industrial scale in small and medium enterprises (SMEs)

Content: From the case study B.1 possible methods or procedures shall be derived which can be more generally used than in the specific example.

Duration: March 2009 – November 2010

T3.1.8. B1 - Validation on a new ERRA related to health effects in medical device industry and application of nature-inspired systems

Content: From the case study B.1 possible methods or procedures shall be derived which can be more generally used than in the specific example

Duration: May 2012 – November 2012

T3.5.2. Medical and public health aspects of emerging risks

Content: provide models and methods (documents) on medical and public health aspects of emerging risks (focus on nanomaterials).

Duration: November 2010 – May 2012